+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 36 Actively Recruiting clinical trials

O

Actively Recruiting

Researchers are collecting real-world data on the Cerene Cryotherapy Device, which was approved by the FDA in 2019 for treating heavy menstrual bleeding in premenopausal women who have completed childbearing. This observational study aims to compare outcomes from routine clinical use of the Cerene device with results from previous pivotal studies, helping to understand its effectiveness and safety in everyday practice. Participants in this registry will have received treatment with the Cerene device as part of their standard medical care. The study does not involve any additional active interventions beyond this treatment. Data collection includes patient and physician surveys covering demographics, quality of life, procedural details, and clinical outcomes following the Cerene treatment. Women will participate for about 13 months, starting from enrollment and continuing through a 12-month follow-up after treatment. During this time, surveys will be completed at multiple points to assess re-intervention rates, quality of life, site of service, physician feedback, and cost analysis. The study concludes after the last participant completes her one-year follow-up visit.

Age: 25Years +FEMALE
2 locations
E

Actively Recruiting

Researchers are investigating the effects of felzartamab in adults who have received kidney transplants and later developed microvascular inflammation MVI, a condition involving injury to small blood vessels in the transplanted kidney that may signal rejection. This condition can lead to serious kidney problems over time and sometimes occurs without the usual antibodies, known as isolated MVI. The study aims to understand how felzartamab influences inflammation in the transplanted kidney and overall kidney health. Participants will be randomly assigned to receive either felzartamab or a placebo through intravenous IV infusions. The study is divided into two parts Part A lasts 24 weeks, during which neither participants nor researchers know who receives felzartamab or placebo Part B lasts an additional 28 weeks where all participants receive felzartamab openly. Kidney biopsies will take place at the start, Week 24, and Week 52 to evaluate changes in inflammation. Participants will be involved for about one year, undergoing regular kidney biopsies, lab tests, and monitoring for adverse events. Researchers will assess inflammation resolution, kidney function, immune activity, and overall health. Safety is closely monitored through biopsies and lab results, with adverse events recorded throughout the trial to ensure thorough evaluation of felzartamabs effects.

Age: 18Years - 74YearsAll GendersPhase 2
51 locations
E

Actively Recruiting

Researchers are evaluating the investigational peptide NVG-291 in adults who have chronic cervical motor-incomplete spinal cord injury. This Phase 3 study aims to learn if NVG-291 can improve hand function and daily activities, and to monitor the safety of the treatment. NVG-291 is designed to promote nervous system repair by targeting pathways that may block nerve regeneration after spinal cord injury. There are no currently approved drugs specifically intended to promote neurological repair in this population. In this randomized, double-blind, placebo-controlled study, approximately 150 participants will be assigned to receive either NVG-291 or a placebo by daily subcutaneous injection for 12 weeks. After the treatment period, participants will be followed for an additional 4 weeks without intervention to assess if any functional improvements persist. An optional open-label extension may allow participants initially on placebo to receive NVG-291. Participants will attend clinic visits for safety checks and assessments of hand function, walking ability, daily activities, and quality of life. Researchers will collect data using tests, questionnaires, and interviews about changes in condition. Safety will be monitored through adverse event recording and laboratory tests. The main outcome is the change in hand function measured by the GRASSP Quantitative Prehension score from baseline to Week 12.

Age: 18Years - 75YearsAll GendersPhase 3
23 locations
T

Actively Recruiting

Researchers are studying acquired dyslexia caused by stroke to see if a computer-based model can predict which type of reading therapy will work best for each person. This early phase 1 trial compares two different treatments using a neural network cognitive model to simulate dyslexia and its treatment. The goal is to find out if following the models treatment recommendation offers an advantage over the alternative therapy. Participants will receive two rounds of therapy, each consisting of 60 hours over about six weeks 5 days a week, 2 hours per day. The therapies tested are Phono-Motor Therapy PMT, which focuses on phonological training with letters and sounds, and Semantic Feature Analysis SFA, which uses word meanings and categories to support reading. One group will get the therapy that matches the models prediction for their reading impairment, while the other group will receive the non-matched therapy first and then switch to the other therapy. During the study, participants will have assessments at the start, after the first 60 hours, and after the final 60 hours of therapy. These include reading tests like the Woodcock Reading Mastery Test and wordpseudoword reading, as well as language and aphasia evaluations. Researchers will closely monitor progress throughout the therapy sessions to measure changes in reading ability and language skills. The entire study allows adults aged 18 to 85 with stroke-related acquired dyslexia to participate and lasts through both treatment rounds and follow-up assessments.

Age: 18Years - 85YearsAll GendersPhase Not Applicable
3 locations
P

Actively Recruiting

Researchers are exploring a treatment for severe spasticity in people with spinal cord injury SCI by implanting a device that delivers electrical stimulation around the spinal cord, called spinal cord epidural stimulation. The study focuses on improving spasticity symptoms like muscle spasms and clonus, especially for those whose condition is not well controlled by oral medications. This approach aims to reduce side effects from current treatments and improve voluntary movement, enhancing quality of life for individuals with chronic SCI. Participants will receive a surgically implanted multi-electrode epidural stimulator placed over the spinal cord. After implant surgery, mapping studies will identify the specific stimulation settings targeting spasticity. The stimulator will then be used at home or in a training facility to manage symptoms. The study includes follow-up assessments at 3 and 6 months post-implant. At the end of the study, participants may choose to have the stimulator removed, turned off, or continue using it for spasm control. Throughout the study, participants will undergo assessments including muscle activity measurements using integrated electromyography EMG, spasm scales, muscle tone scores, and safety monitoring over approximately 11 months. Evaluations occur before implantation and at 3- and 6-month intervals after surgery and device training. This comprehensive monitoring helps researchers understand the effects of spinal cord epidural stimulation on spasticity and voluntary movement in daily life.

Age: 22Years +All GendersPhase Not Applicable
1 location
E

Actively Recruiting

Healthy Volunteer

Researchers are investigating cardiovascular function changes during the first year after a spinal cord injury SCI, focusing on how blood pressure responds to spinal cord transcutaneous stimulation scTS. The study targets individuals with recent SCI who have low blood pressure and orthostatic hypotension, aiming to determine the best timing to start scTS and understand how cardiovascular activation evolves over time. The study includes both inpatient and outpatient phases, with detailed autonomic function testing to assess blood pressure and autonomic responses. Participants receive scTS using a 5-channel electrical stimulator starting shortly after injury, with sessions occurring regularly over one year. The inpatient phase involves 5-11 sessions including autonomic questionnaires, 24-hour blood pressure monitoring, cold pressor tests, and tilt tests with and without stimulation, along with 2-3 days of stimulation mapping. The outpatient phase includes 15-18 sessions with monthly mapping and autonomic assessments, plus comprehensive testing at 6, 9, and 12 months post-injury. A supplementary spin-off study compares two cooling methods ice-water immersion and ice-wrap in different body positions to find the most consistent blood pressure response. Participants undergo multiple assessments such as 70-degree tilt tests, cold pressor tests, autonomic dysfunction questionnaires, and 24-hour ambulatory blood pressure monitoring at regular intervals throughout the year. Blood pressure and electromyography are monitored continuously during stimulation to maintain target blood pressure levels. The study tracks blood pressure response to stimulation, orthostatic hypotension symptoms, and autonomic dysfunction development. The total study duration covers about 20-29 sessions from inpatient stay to outpatient follow-up extending up to one year post-injury.

Age: 18Years - 75YearsAll GendersPhase Not Applicable
1 location
S

Actively Recruiting

This trial investigates new learning and memory impairment NLMI in people with moderate to severe traumatic brain injury TBI. The study evaluates whether combining aerobic exercise training AET with the Kessler Foundation modified Story Memory Technique KF-mSMT improves memory, brain function, and daily life outcomes better than KF-mSMT with stretching exercises. The goal is to find more effective ways to help individuals with TBI regain memory abilities and improve quality of life. Participants are randomly assigned to one of two groups one receiving KF-mSMT alongside supervised aerobic cycling, and the other receiving KF-mSMT with supervised stretching and toning exercises. Both interventions occur three days per week for 12 weeks, with the cognitive rehabilitation starting after the first 4 weeks of exercise. Each session starts at 15 minutes and gradually increases to 2 hours by the end of the program. During the study, participants will be regularly assessed using memory tests, brain MRI scans focusing on the hippocampus, and everyday memory simulations to measure progress. The primary outcome is change in verbal learning test performance over 12 weeks. Safety and adherence will be monitored while participants complete questionnaires and cognitive evaluations. The study lasts 12 weeks, with ongoing evaluation of how these combined treatments affect memory and brain health in TBI patients.

Age: 18Years - 65YearsAll GendersPhase 1
1 location
T

Actively Recruiting

Researchers are evaluating a new combined approach to improve reading difficulties in people who have had a stroke and suffer from aphasia. This randomized controlled trial focuses on individuals with chronic left-hemisphere stroke who have ongoing reading deficits. The goal is to test whether adding aerobic exercise to targeted reading therapy can enhance brain circulation and strengthen damaged neural networks involved in reading. This study aims to improve reading and language abilities beyond what current treatments achieve, potentially advancing stroke recovery methods. Participants will be randomly assigned to one of two groups. One group will receive 40 sessions of phono-motor therapy combined with 20 minutes of moderate aerobic cycling exercise per session, administered 4-5 times weekly. The other group will receive the same phono-motor therapy combined with 20 minutes of light stretching instead. Each session lasts about 2 hours, including warm-up and cool-down periods. The intervention is designed to engage multiple senses and motor skills to rebuild reading abilities. During the study, participants will undergo three MRI scans before starting treatment, after the first exercise session, and after completing all 40 sessions. Behavioral testing will also be conducted before and after the intervention to assess reading skills. Researchers will measure reading aloud accuracy, comprehension, brain blood flow, and brain activity related to reading tasks. Participants will keep logs of their exercise or stretching sessions to track effort. The study will last about 10 weeks from beginning to end, with close monitoring of progress and treatment effects.

Age: 18Years - 85YearsAll GendersPhase Not Applicable
1 location
T

Actively Recruiting

Researchers are studying the safety and practicality of spinal cord transcutaneous stimulation scTS combined with activity-based training ABT for people with acute to subacute cervical spinal cord injury SCI during inpatient rehabilitation. The trial aims to see if this combined approach is safe, feasible, and whether it improves hand, arm, and trunk function better than ABT alone or a sham stimulation control. The study also explores changes in brain and spinal cord activity to understand how these treatments may work. Participants are randomly assigned to one of three groups scTS with ABT, sham scTS with ABT, or ABT only. Treatments are given over 10 sessions across 2 weeks, each lasting 30 minutes as part of daily therapy. The active scTS involves skin electrodes delivering mild stimulation to the cervical and thoracic spine, adjusted for comfort without visible muscle contractions. The sham group receives a brief, low-level stimulation to mimic sensations without therapeutic effects, while the ABT group focuses on upper limb motor tasks like grasping and pinching. Participants undergo assessments before, during, and after the intervention, plus follow-ups at 1, 2, and 3 months. Safety is monitored by tracking pain, skin condition, adverse events, and vital signs. Functional outcomes include hand strength and upper limb motor skills measured by specific tests. Researchers also evaluate study completion rates and will compare changes in cortical and spinal excitability to assess the interventions impact. The total study duration for each participant is about 3 months from start to final follow-up.

Age: 18Years - 75YearsAll GendersPhase Not Applicable
1 location
S

Actively Recruiting

Researchers are evaluating the Q Therapeutic System BQ 3.0, a wearable medical device that delivers very low-intensity, frequency-tuned electromagnetic fields to stimulate brain networks. This study aims to assess whether this treatment can reduce disability and promote recovery in adults who have experienced an ischemic stroke. The study is conducted across multiple centers and compares active treatment with a sham inactive device in a randomized, double-blind design. The study begins 4 to 21 days after the stroke event. In the first stage up to day 90 post-stroke, participants receive either active or sham treatments five times a week, totaling at least 45 sessions. In the second stage day 90 to day 180, all participants who completed stage 1 can continue to receive active treatments up to five times weekly. In the third stage day 180 to day 270, no treatments are given, and participants are monitored until the final visit. Each session lasts about 60 minutes, including 40 minutes of device use combined with a home-based exercise program. Participants will be trained, with caregiver support as needed, to use the device and perform exercises at home. The study team provides periodic remote supervision and technical support. Assessments of recovery and function will occur at multiple points, including days 45, 90, 180, and 270 after the stroke. Researchers will monitor safety by recording any adverse events or device issues. Usual medical care continues alongside the study treatments throughout the participation period.

Age: 22Years - 80YearsAll GendersPhase Not Applicable
14 locations

1-10 of 36

1